Gifted with attention-deficit on a half-decade cycle, and a need to build things and understand how they work, Martin has had a wide range of careers over more than three decades.

Moving from academic researcher (PhD Toronto, Postdoctoral studies Yale) to biotechnologist, he developed three drug candidates for therapy and imaging that entered clinical studies. In bioinformatics he founded a second, venture-backed startup, before focusing on the application of knowledge management as it became enabled by the then emerging enterprise content management (ECM) field.

Currently in enterprise content architecture, he has tested community strategies in real-life implementations of staff and customer communities.

Work History

Work History
2007 - Present

VP, Enterprise Content Architecture
  • Reporting to the CEO and responsible for the coordinated application of Open Text solutions internally, and the development and dissemination of enterprise content management (ECM) best practices
2005 - 2007

VP, Customer Partnership Programs

  • Developed a unified brand, Open Text Online, for all customer support activities online
  • Introduced and managed Open Text Online Communities, which became the principal source of customer leads (radiate strategy)
  • Executive sponsor for Open Text corporate website, GlobalStar customer rewards and reference program, NewsLink newsletter
  • Worked with Executive Chairman to develop strategic transformation of the company to a solutions vendor in response to trends in the maturing ECM market
2001 - 2005

VP, Pharmaceutical & Life Sciences Solutions

  • When I joined Open Text the company had very little penetration in the life sciences market. Over five years total revenues grew over 600% and the company enjoyed major success, and global sales in this segment accounted for ~10% of all corporate revenues
  • Success was based on the development of targeted extension of the Open Text Livelink ECM platform that addressed specific customer needs to manage corporate documents and records in compliance with FDA and equivalent regulatory requirements
1996 - 2001

President & CEO

  • Raised approximately C$9 million from VC investors to spin-off from Allelix
  • Originally started to provide bioinformatics services to biotechnology companies, Base4 was repositioned as the leading company providing project life-cycle solutions for pharmaceutical and biotechnology R&D
  • Clients for Base4's PharMatrix solutions included multinational pharmaceutical companies and biotechnology companies of all sizes
  • Staff grew to 38 by mid-2000, with offices in the US, Canada and Switzerland. The Company was acquired by Open Text in early 2001 to drive life sciences initiative
1984 - 1996

From Research Scientist to Director


1982 - 1984

Post-doctoral Fellow

1977 - 1982


1974 - 1977


1971 - 1974